Nightingale Health Plc – Managers’ transactions – Olli Karhi
Nightingale Health Plc
Managers' Transactions
4 July 2024 14:35 p.m. (EEST)
|
Person subject to the notification requirement |
|
Name: Cor Group Oy |
|
Position: Closely associated person |
|
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer |
|
Name: Olli Karhi |
|
Position: Member of the Board |
|
Issuer: Nightingale Health Oyj |
|
LEI: 743700WUIPC24LVMLO66 |
|
Notification type: INITIAL NOTIFICATION |
|
Reference number: 69373/7/8 |
|
|
|
____________________________________________ |
|
Transaction date: 2024-07-03 |
|
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) |
|
Instrument type: SHARE |
|
ISIN: FI4000490875 |
|
Nature of transaction: ACQUISITION |
|
|
|
Transaction details |
|
(1): Volume: 536842 Unit price: 2 EUR |
|
|
|
Aggregated transactions (1): |
|
Volume: 536842 Volume weighted average price: 2 EUR |
For further information, please contact:
Teemu Suna, CEO
[email protected]
Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
